Koss Olinger Consulting LLC Has $4.86 Million Stock Position in Pacific Biosciences of California, Inc. $PACB

Koss Olinger Consulting LLC lowered its stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 21.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 2,600,000 shares of the biotechnology company’s stock after selling 700,000 shares during the period. Koss Olinger Consulting LLC’s holdings in Pacific Biosciences of California were worth $4,862,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new stake in shares of Pacific Biosciences of California in the 3rd quarter valued at $524,000. Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Pacific Biosciences of California by 97.9% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 808,700 shares of the biotechnology company’s stock valued at $1,035,000 after buying an additional 400,000 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in shares of Pacific Biosciences of California by 63.3% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 1,288,692 shares of the biotechnology company’s stock valued at $1,650,000 after buying an additional 499,421 shares in the last quarter. UBS Group AG increased its position in shares of Pacific Biosciences of California by 111.8% in the 4th quarter. UBS Group AG now owns 3,171,546 shares of the biotechnology company’s stock valued at $5,931,000 after buying an additional 1,674,320 shares in the last quarter. Finally, Intech Investment Management LLC increased its position in shares of Pacific Biosciences of California by 5.2% in the 3rd quarter. Intech Investment Management LLC now owns 132,368 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 6,564 shares in the last quarter.

Pacific Biosciences of California Trading Up 1.4%

PACB stock opened at $1.49 on Friday. The stock has a 50-day moving average price of $1.42 and a two-hundred day moving average price of $1.76. The stock has a market cap of $462.79 million, a PE ratio of -3.47 and a beta of 2.40. Pacific Biosciences of California, Inc. has a 1 year low of $0.96 and a 1 year high of $2.73.

Pacific Biosciences of California (NASDAQ:PACB) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. The company had revenue of $37.18 million for the quarter, compared to analyst estimates of $39.94 million. Pacific Biosciences of California had a negative return on equity of 571.06% and a negative net margin of 80.35%. On average, analysts forecast that Pacific Biosciences of California, Inc. will post -0.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on PACB shares. Barclays upped their price objective on shares of Pacific Biosciences of California from $1.00 to $1.50 and gave the company an “underweight” rating in a research report on Monday, May 11th. Zacks Research cut shares of Pacific Biosciences of California from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $1.83.

Pacific Biosciences of California Profile

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.